Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene + PUVA in Stage IB-IIA CTCL
NCT00030589Phase 2Unknown
- Sponsor
- Millennix
- Start
- Feb 2001
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bexarotene in cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by Millennix. Primary endpoints: Efficacy of Bexarotene + PUVA at 26 weeks and Safety of Bexarotene + PUVA at 30 weeks. Status: unknown.
02
Drugs
bexarotene
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00030589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030589.